Genmab shelves Phase III lung cancer candidate
Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.
Therapy Area
Sanofi buys hep B vaccine maker for $2.2bn
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
UK approves Gilead’s twice-yearly HIV PrEP drug
Nxera seeks schizophrenia programme buyer after Boehringer snub
CDC ends universal newborn hepatitis B vaccine recommendations
Precision medicine approaches needed in oncology to match evolving SoC
First gonorrhoea antibiotics in decades herald new era of treatment
